diabetes
FDA panel backs liraglutide for obesity
September 12, 2014Manufacturing and Production, Sales and Marketing Arena Pharmaceuticals, Belviq, Novo Nordisk, Qsymia, Victoza, Vivus, diabetes, obesity
An FDA panel has voted 14-1 to allow a form of Novo Nordisk’s type 2 diabetes treatment Victoza to help …
Lilly and Boehringer diabetes biosimilar sees EU approval
September 11, 2014Sales and Marketing Boehringer, EU, European Commission, Lantus, Sanofi, diabetes, lilly
Lilly and Boehringer Ingelheim’s insulin glargine product has been shown the green light by the European Commission (EC). The copycat …
Trial misconduct halts Evotec/Hyperion drug
September 10, 2014Research and Development, Sales and Marketing DiaPep277, Evotec, amdromeda, diabetes, hyperion
Development of Evotec and Hyperion Therapeutic’s diabetes drug DiaPep277 has been terminated following ‘serious misconduct’ in one of its trials. …
Novo Nordisk scraps inflammatory disorders business
September 2, 2014Research and Development, Sales and Marketing Danish, IL20, Novo Nordisk, diabetes, inflammatory, thomsen
A restructuring of Novo Nordisk will see it completely drop its inflammatory disorders activities in favour of concentrating on its …
AZ and Mitsubishi partner on diabetic nephropathy
August 20, 2014Research and Development, Sales and Marketing AstraZeneca, BMS, Mitsubishi, cvmd, diabetes, nephropathy
AstraZeneca and Japanese firm Mitsubishi Tanabe Pharma Corporation (MTPC) have signed a new three-year research deal in the area of …
Sanofi signs $925 million inhaled insulin deal
August 13, 2014Sales and Marketing Afrezza, French, Sanofi, diabetes, fad, insulin
Sanofi could pay out as much as $925 million for global rights to the world’s only approved inhaled insulin just …
Cost of diabetes treatment soars in England
August 13, 2014Medical Communications, Research and Development, Sales and Marketing Lantus, NHS, Sanofi, diabetes
The NHS spent more than £2.2 million on average every day over the last financial year on diabetes medicines, according …
Novartis forms alliance with Google on ‘smart lens’
July 15, 2014Medical Communications, Sales and Marketing Alcon, Novartis, diabetes, e-health, google, smart lens, wearable
Novartis eye care division Alcon has struck a deal with Google to develop a ‘smart’ contact lens designed to help …
Rise in diabetes ‘alarming’
July 7, 2014Sales and Marketing NHS, diabetes, nhs scotland, type 2
NHS Scotland has spent around £230 million on diabetes and obesity drugs in the past three years, according to data …
FDA ‘yes’ to inhaled insulin
June 30, 2014Manufacturing and Production, Sales and Marketing Afrezza, FDA, Mannkind, diabetes, insulin human
The FDA has approved the first ‘ultra-rapid-acting’ mealtime insulin therapy available in the US, to improve glycemic control in both …
NICE recommends tenth diabetes drug
June 26, 2014Sales and Marketing Janssen, NHS, diabetes, invokana, type 2
In final guidance NICE has recommended Janssen’s Invokana as a treatment to help lower blood sugar levels in people with …
Sanofi and Medtronic partner on diabetes
June 16, 2014Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, diabetes, medtronic
Sanofi and Medtronic have announced a new tie-up that will see both firms develop new products in the increasingly competitive …
Novo Nordisk outlines hiring plans
June 12, 2014Sales and Marketing Denmark, Novo Nordisk, diabetes, haemostasis, pharma
Novo Nordisk has outlined ambitious plans for the medium-term, saying it will look to hire 6,000 staff in its native …
Sales forecasts leave Sovaldi top and Januvia lagging
May 23, 2014Sales and Marketing Gilead, Januvia, Merck, diabetes, ep, hep C, sovaldi
Sovaldi has topped analysts’ estimates for future growth but Merck’s big-selling diabetes drug Januvia is falling by the wayside. This …
Inhaled insulin one step closer to approval
April 3, 2014Sales and Marketing Afrezza, FDA, Mannkind, diabetes, type 1, type 2
After a rocky few years MannKind’s inhaled insulin Afrezza finally looks to be on the path to approval in the …
Latest content
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner
